Ganitumab
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor, designed for the treatment of cancers.
Ganitumab was developed by Amgen. A phase III clinical trial was abandoned in August 2012.
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor, designed for the treatment of cancers.
Ganitumab was developed by Amgen. A phase III clinical trial was abandoned in August 2012.